First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Published:2024-06 Issue:6 Volume:25 Page:744-759
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fürstenau Moritz,Kater Arnon P,Robrecht Sandra,von Tresckow Julia,Zhang Can,Gregor Michael,Thornton Patrick,Staber Philipp B,Tadmor Tamar,Lindström Vesa,Juliusson Gunnar,Janssens Ann,Levin Mark-David,da Cunha-Bang Caspar,Schneider Christof,Goldschmidt Neta,Vandenberghe Elisabeth,Rossi Davide,Benz Rudolf,Nösslinger Thomas,Heintel Daniel,Poulsen Christian B,Christiansen Ilse,Frederiksen Henrik,Enggaard Lisbeth,Posthuma Eduardus F M,Issa Djamila E,Visser Hein P J,Bellido Mar,Kutsch Nadine,Dürig Jan,Stehle Alexander,Vöhringer Matthias,Böttcher Sebastian,Schulte Clemens,Simon Florian,Fink Anna-Maria,Fischer Kirsten,Holmes Emily E,Kreuzer Karl-Anton,Ritgen Matthias,Brüggemann Monika,Tausch Eugen,Stilgenbauer Stephan,Hallek Michael,Niemann Carsten U,Eichhorst Barbara

Funder

Janssen Pharmaceuticals Inc

AbbVie Inc

Roche

Publisher

Elsevier BV

Reference29 articles.

1. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities;Kater;NEJM Evid,2022

2. First-line venetoclax combinations in chronic lymphocytic leukemia;Eichhorst;N Engl J Med,2023

3. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions;Fischer;N Engl J Med,2019

4. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia;Seymour;N Engl J Med,2018

5. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial;Tam;Lancet Oncol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia;The Lancet Oncology;2024-06